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Abstract
Background: Campylobacter jejuni is the predominant antecedent infection in Guillain-Barre´ syndrome (GBS). Molecular
mimicry and cross-reactive immune responses to C. jejuni lipo-oligosaccharides (LOS) precipitate the development of GBS,
although this mechanism has not been established in patients from developing countries. We determined the carbohydrate
mimicry between C. jejuni LOS and gangliosides, and the cross-reactive antibody response in patients with GBS in
Bangladesh.
Methodology: Sera from 97 GBS patients, and 120 neurological and family controls were tested for antibody reactivity
against LOS from C. jejuni isolates from GBS patients in Bangladesh (BD-07, BD-39, BD-10, BD-67 and BD-94) by enzyme-
linked immunosorbent assay (ELISA). Cross-reactivity to LOS was determined by ELISA. The LOS outer core structures of C.
jejuni strains associated with GBS/MFS were determined by mass spectrometry.
Principle Findings: IgG antibodies to LOS from C. jejuni BD-07, BD-39, BD-10, and BD-67 IgG antibodies were found in serum
from 56%, 58%, 14% and 15% of GBS patients respectively, as compared to very low frequency (,3%) in controls (p,0.001).
Monoclonal antibodies specific for GM1 and GD1a reacted strongly with LOS from the C. jejuni strains (BD-07 and BD-39).
Mass spectrometry analysis confirmed the presence of GM1 and GD1a carbohydrate mimics in the LOS from C. jejuni BD-07
and BD-39. Both BD-10 and BD-67 express the same LOS outer core, which appears to be a novel structure displaying GA2
and GD3 mimicry. Up to 90–100% of serum reactivity to gangliosides in two patients (DK-07 and DK-39) was inhibited by
50 mg/ml of LOS from the autologous C. jejuni isolates. However, patient DK-07 developed an anti-GD1a immune response
while patient DK-39 developed an anti-GM1 immune response.
Conclusion: Carbohydrate mimicry between C. jejuni LOS and gangliosides, and cross-reactive serum antibody precipitate
the majority of GBS cases in Bangladesh.
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Introduction
Guillain-Barre´ syndrome (GBS) is an acute post-infectious
immune-mediated peripheral neuropathy with a marked variation
in pathology, clinical presentation and prognosis [1]. Although
poliomyelitis has been eradicated in Bangladesh, non-polio acute
flaccid paralysis (AFP) cases are still frequently diagnosed. The
majority of the non-polio AFP cases are diagnosed as GBS [2].
The crude incidence rates of GBS among children ,15 years of
age varied from 1.5 to 1.7 per 100,000 per year in Bangladesh [2].
This crude incidence rate of GBS appeared to be 2.5 to 4 times
higher than that other parts of the world [2]. Campylobacter jejuni is
recognized as the most common pathogen associated with GBS
and Miller Fisher syndrome (MFS) [3,4,5,6].
The exact pathogenesis of post-Campylobacter neuropathy such as
GBS is not clearly understood, however, molecular mimicry
between Campylobacter lipo-oligosaccharides (LOS) and gangliosides
in nervous tissue induces a cross-reactive antibody response [7,8].
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Antibody reactivity against GM1, GM1b, and GalNAc-GD1a is
associated with pure motor GBS [9], and anti-GQ1b antibody
reactivity has a strong association with oculomotor symptoms and
ataxia [10]. The oligosaccharide core of LOS molecules expressed
by C. jejuni structurally resemble the oligosaccharide core of certain
molecules present in neural tissue [11,12]. Many studies have been
carried out in the developed world to establish the pathogenesis of
C. jejuni-induced GBS but little information is available concerning
the pathogenic mechanism in neuropathy-associated strains from
developing countries such as Bangladesh.
Recently, we reported an unusually high frequency of acute
motor axonal neuropathy (AMAN) variant of GBS in Bangladesh,
associated with preceding C. jejuni infections and the presence of
serum antibodies against GD1a and GM1 [6]. Unfortunately, for
many patients in Bangladesh the current standard treatment for
GBS are too expensive. To develop more effective and targeted
therapies, improved understanding of GBS pathogenesis is re-
quired. The aim of the present study was to investigate the role of
molecular mimicry and cross-reactive IgG responses in GBS in
Bangladesh. The LOS outer core of C. jejuni strains isolated from
these patients was characterized for the presence of ganglioside like
structures. In addition, sera from patients with GBS and controls
were screened for antibodies to C. jejuni LOS and the cross-
reactivity to gangliosides.
Materials and Methods
Patients and Controls
In this study 100 consecutive patients with GBS or MFS were
admitted to Dhaka Medical College Hospital (DMCH), Banga-
bandhu Sheikh Mujib Medical University (BSMMU) and Dhaka
Central Hospital (DCH) between July 2006 and June 2007 [6]. All
patients fulfilled the diagnostic criteria for GBS [13], as evaluated
by a neurologist and a senior neurologist [6]. Data were collected
prospectively on age, sex, antecedent events, detailed neurological
signs and symptoms, treatment, days to nadir, complications,
duration of admission and clinical disease severity (expressed for
weakness as Medical Research Council (MRC) sum score and for
disability as the GBS disability score measured at entry. Two types
of controls were selected for patients: the first control was a family
member living in the same household (family control, FC); the
second control was an age and sex matched patient hospitalized in
the same ward with other neurological disease (OND). Blood and
up to three stool samples were collected from all patients and
controls. All studies were approved by the ethical committee of
Dhaka Medical College, Dhaka and all patients gave written
informed consent [6].
C. jejuni and Lipo-oligosaccharides
C. jejuni was isolated from stool specimens of 10 patients with
GBS or MFS [14]. Five of these C. jejuni isolates were selected for
serological studies and definition of the molecular mimicry. The
clinical features and laboratory findings of these patients are given
in Table 1. The C. jejuni isolates, BD-07, BD-10, BD-39, BD-67
and BD-94 [14], were classified according to the heat-stable (HS)
serotyping system developed by Penner [15]. The LOS fraction
from all C. jejuni strains was isolated by hot phenol-water extraction
and processed as described before [16,17]. LOS from the C. jejuni
serostrain HS:03 (CCUG 10937), lacking gangliosides mimicry
[11], was included for control studies.
Antibody Reactivity to C. jejuni LOS
Pre-treatment, acute phase serum samples from 97 of these 100
GBS patients, including the 5 patients from whom C. jejuni was
isolated, were available for serological studies. Serum samples from
60 family controls (FC) and 60 controls with other neurological
disease controls (OND) were analysed. The sera were tested for
IgG, IgM and IgA activity against LOS from C. jejuni (BD-07, BD-
10, BD-39, BD-67, BD-94 and CCUG 10937) in ELISA. Serum
antibodies against LOS were tested in ELISA as described earlier
[18,19] with some modifications. In brief, a 96-well polystyrene
microtitre trays (Immuno Maxisorb, Nunc) was coated with 1 mg
of LOS in 50 ml PBS (pH=7.8) per well, and incubated overnight
at 37uC. Non-specific binding sites were blocked with PBS
containing 1% BSA (Sigma) for 2 hours at room temperature,
and for another 2 hours at 4uC. After blocking, the plates were
incubated overnight at 4uC with serum diluted 1:1000 in PBS–1%
BSA. After washing with PBS (pH=7.8), the plates were
incubated with peroxidase-conjugated rabbit anti-human IgG,
IgA and IgM antibody (Sanbio) diluted 1:2500 in PBS-1% BSA,
for 90 min at room temperature. After washing with PBS, the
plates were developed with O-phenyl diamine (Sigma) in citrate
buffer (pH 5.1) and the optical densities (ODs) were read at
492 nm. Each individual serum sample was tested in triplicate, this
test means that each serum sample was tested in 3 LOS-coated
wells and 3 blank wells in the same ELISA. The mean absorbance
value for triplicate reference wells without antigen was subtracted
from the mean value for triplicate sample wells with the antigen. A
serum was considered positive for anti-LOS reactivity when the
corrected OD was higher than the mean value of controls plus 3
times standard deviation (SD). All serological studies were
performed blinded for clinical data.
Table 1. Clinical and laboratory findings in five patients with
Guillain-Barre´ syndrome from whom Campylobacter jejuni was
isolated and used in the current studya.
Patients BD-39 BD-07 BD-10 BD-67 BD-94
Clinical
characteristics
Age (years) 30 40 15 40 10
Sex F M M M F
Diarrhoea + + + + –
Days to nadir 12 2 5 6 3
Ophthalmoplegia – – + + –
Sensory deficits – – – – –
Motor deficits + + + + +
GBS disability score
At nadir 5 4 5 4 5
At 26 weeks 4 0 3 3 4
Serology
Anti-GM1 IgG + – – + –
Anti-GD1a IgG – + + + –
Anti-GQ1b IgG – – + + –
C. jejuni serology + + + + +
C. jejuni isolates
Penner serotype HS:19 HS:19 HS:23 HS:23 HS:21
a. Abbreviations: M, Male; F, Female; +, present; -, absent; N, normal, GBS
disability score (6).
doi:10.1371/journal.pone.0043976.t001
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Antibody Reactivity to Gangliosides
Pre-treatment serum samples obtained upon hospitalization
were available from 97 of these 100 patients and 120 controls to
determine the presence of IgM and IgG antibodies to the
gangliosides GM1, GD1a and GQ1b by ELISA according to
methods and criteria for positivity previously described [20].
Determination of Cross-reactivity
Cross-reactivity of anti-ganglioside antibodies to C. jejuni LOS
was determined by pre-incubation of serum with LOS from the C.
jejuni isolated from the autologous patients and with LOS from the
C. jejuni serostrain HS:03 (CCUG 10937) as a control, according to
methods previously described [17]. To detect cross-reactive
antibodies, serum DK-07 (diluted 1:100) and DK-39 (diluted
1:100) were pre-incubated with LOS from their autologous C. jejuni
isolate and as a control with LOS from the C. jejuni serostrain
HS:03 (CCUG 10937). C. jejuni LOS concentrations of 200, 50,
12.5, 3.1, 0.8 and 0.2 mg/ml were incubated with serum for 3
hours at 4uC. After the incubation with LOS, the sera were
centrifuged at 3000 rpm for 5 minutes at 4uC. The supernatants
were tested for residual anti-ganglioside IgG reactivity by ELISA.
The percentage of inhibition was defined as:
OD serumwithout LOSð Þ{OD serumwithLOSð Þ
OD serumwithout LOSð Þ |100%
Mass Spectrometry Analysis
LOS fractions from C. jejuni BD-07, BD-10, BD-39, BD-67 and
BD-94 were prepared for mass spectrometric analysis. These C.
jejuni strains were grown overnight at 37uC on Butzler agar plates
in a microaerobic atmosphere. Material from one confluent agar
plate was harvested and treated with proteinase K at 60 mg/ml,
RNase A at 200 mg/ml, and DNase I at 100 mg/ml (Promega,
Leiden, The Netherlands). O-deacylated LOS samples were
prepared and analyzed by capillary electrophoresis coupled to
electrospray ionization mass spectrometry (CE-ESI-MS) [21].
Statistical Analysis
Differences in median values were tested with the Mann-
Whitney U test. Differences in proportions were tested with the chi
square test or Fisher’s exact test. Differences were considered
significant at p,0.05 after two-sided testing. Statistical analysis
was performed using InStat version 4.0 (Graphpad Software, San
Diego, CA).
Results
Antibodies to C. jejuni LOS
The IgG reactivity in serum from the patients with GBS, and
the FC and OND control groups to C. jejuni LOS is shown in
Figure 1. IgG antibodies to LOS from BD-07, BD-39, BD-10, and
BD-67 IgG were found in sera from 56%, 58%, 14% and 15% of
GBS patients respectively, compared to very low frequencies
(,3%) of controls (all p,0.001). Except for three cases, no sera
from GBS patients and controls were positive for anti-LOS BD-94
IgG. The IgG activity to LOS from the control C. jejuni HS:03
serostrain CCUG 10937 in serum from the GBS patients did not
differ from that in the two control groups. Serum IgA antibodies to
LOS from BD-07 and BD-39 were found in 50% and 48% of GBS
patients, respectively, compared 0% in OND and 4% in FC in
controls (p,0.001) (data not shown). Serum IgM antibodies to
LOS from BD-07 were found in 22% of GBS patients, compared
to 4% of OND controls (p=0.052) and 0% of family controls
(p=0.012) (data not shown). Serum IgM antibodies to LOS from
BD-39 antibodies were found in 20% of GBS patients, in 4% of
OND controls (p=0.088) and in 0% of family controls (p=0.025)
(data not shown). In addition, diarrhea in the four weeks preceding
GBS was reported in 26 (48%) of the 54 patients with IgG to C.
jejuni LOS compared to 10 (23%) of 43 of the without anti-LOS
patients (P = 0.02).
Antibodies to Gangliosides
Serum antibodies to the ganglioside GM1, GD1a and GQ1b
were more frequent in GBS patients (56%) compared to OND
(1%) and FC (6%), p,0.001) [6]. The GBS patients were divided
into two subgroups according to their anti-ganglioside reactivity:
one group with anti-GM1 and/or anti-GD1a antibodies and
another group without these antibodies. Anti-LOS reactivity was
significantly associated with the presence of anti-ganglioside
antibodies (p,0.001) (Table 2). Diarrhea in the four weeks
preceding GBS was reported in 26 (48%) of the 54 ganglioside-
positive patients, which was more frequent compared to the 10
(19%) of 43 of the ganglioside-negative patients (P,0.01) (Table 2).
There was no association between anti-GM1/GD1a serology and
sex, age, degree of overall disability of arms, facial, and bulbar
weakness at the peak of the illness.
Monoclonal Anti-ganglioside Antibodies Cross-reacting
with C. jejuni LOS
Monoclonal mouse antibodies against different gangliosides
were used to determine if ganglioside-mimics were present in the
LOS. Monoclonal antibodies DG-1 (binding to GM1), and TBG-3
(binding to GD1a) reacted strongly with LOS from the C. jejuni
strains (BD-07 and BD-39 respectively) as shown in Figure 2.
These serological data indicate that C. jejuni BD-07 and BD-39
both have a GM1 and/or GD1a mimicking LOS. Control studies
with monoclonal antibodies EG-7 (binding to GD1b), EG-3
(binding to GQ1b/GT1a) and EG-1 (binding to GQ1b) did not
bind to the LOS, demonstrating that BD-07 and BD-39 have no
GD1b, GQ1b or GQ1b/GT1a mimicry. The monoclonal
antibodies bound to positive control C. jejuni LOS with known
ganglioside-mimics (data not shown). None of the antibodies were
bound by the LOS from either C. jejuni CCUG 10937 (negative
control) or from BD-10, BD-67 and BD-94.
Cross-reactive Antibodies to C. jejuni LOS and
Gangliosides in GBS Patients
Serum DK-07 and serum DK-39 showed reduced anti-ganglio-
side IgG antibody reactivity after pre-incubation with LOS from
their autologous C. jejuni isolates (Figure 3). SerumDK-07 was tested
for residual anti-GD1a IgG antibodies, whereas serum DK-39 was
tested for anti-GM1 IgG antibodies. The percentage of inhibition of
anti-ganglioside reactivity was dose-dependent with the LOS
concentration. About 50% of inhibition was seen after pre-
incubation with 3.1 mg/ml of LOS BD-07 and with 12.5 mg/ml of
LOS BD-39. In control studies, LOS from C. jejuni Penner HS:03
serostrain (CCUG 10937) did not inhibit the ganglioside antibodies
of serumDK-07 and DK-39, indicating that the cross-reactive anti-
ganglioside antibodies showed no specific binding to the LOS from
C. jejuni CCUG 10937 (Figure S1).
Ganglioside Mimicry of C. jejuni LOS
CE-ESI-MS of O-deacylated LOS was used to define the LOS
outer core structures from five C. jejuni strains (Figure 4 and Table
Ganglioside Mimicry and Cross-Reactive Antibodies
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Figure 1. Serum samples from patients with GBS and from controls with other neurological disease (OND) and family controls (FC)
were tested for IgG activity to lipo-oligosaccharides (LOS) from 6 C. jejuni. Subcharts represent serum IgG activity to LOS from (A) C. jejuni
BD-07 isolated from a GBS patient (B) C. jejuni BD-39 isolated from a GBS patient, (C) C. jejuni BD-10 isolated from a GBS/MFS patient, (D) C. jejuni BD-
67 isolated from a GBS/MFS patient, (E) C. jejuni BD-94 isolated from a GBS patient (F) C. jejuni Penner HS:03 serostrain (CCUG 10937), lacking
ganglioside mimics, as a control. *p,0.001. Lines () indicate cut-off value. GBS, Guillain-Barre´ syndrome; OND, other neurological disease; FC, family
controls; LOS, lipo-oligosaccharides.
doi:10.1371/journal.pone.0043976.g001
Table 2. Clinical characteristics of GBS patients associated with presence IgM and/or IgG antibodies in serum to the gangliosides
GM1, GD1a and GQ1b*.
Serum IgM and/or IgG antibodies to GM1, GD1a and/or GQ1b
Positive (N=54) Negative (N=43) Odds ratio (95% CI) P-value{
Clinical features
Age (median) 18 (2–52) 21 (5–65) – n.s.
Sex 41M/13F 29M/14F 1.07 (0.4–2.86) n.s.
Preceding diarrhea 26 (48%) 10 (19%) 3.06 (1.6–8.2) ,0.02
Ventilation 10 (18%) 13 (30%) 0.56 (0.2–1.5) n.s.
Sensory deficit at entry 0 (0%) 8 (14%) – 0.001
C. jejuni infections
Positive C. jejuni serology 43 (80%) 12 (28%) 10.1 (3.6–29.1) ,0.001
Positive anti-LOS serology 47 (87%) 10 (23%) 22.1 (6.9–75.5) ,0.001
Electrophysiology (N=64)
AMAN, AMSAN{ 28/42 (67%) 15/22 (68%) 0.9 (0.3–3.2) n.s.
AIDP1 8/42 (19%) 6/22 (27%) 0.8 (0.5–1.4) n.s.
Unclassified 6/42 (14%) 1/22 (5%) 3.5 (0.4–82.5) n.s.
*Data were expressed as median or number of patients (percentage); M, male; F, female; CI, confidence interval; – cannot be calculated.
{Determined by Chi-square or Fisher’s exact test.
"Determined by Wilcoxon-Mann-Whitney U test.
{Axonal variants: acute motor axonal neuropathy (AMAN), acute motor sensory axonal neuropathy (AMSAN).
1AIDP, acute inflammatory demyelinating polyneuropathy.
doi:10.1371/journal.pone.0043976.t002
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S1). The CE-ESI-MS did not provide linkage information but
provided information about the sugar composition of the LOS
outer core. The glycosyltransferase variants present in the LOS
locus of each strain (Table 3) and the comparison with strains of
known LOS outer core structures were used to propose LOS outer
core structures for four strains (BD-07, BD-10, BD-39 and BD-67).
The CE-ESI-MS data were not sufficient to propose a structure in
the case of BD-94. However, we can conclude that the LOS outer
core of BD-94 does not show ganglioside mimicry because no
major ion was observed in a precursor ion mass spectrum at m/z
290.2 (data not shown), confirming that there is no sialic acid
present. The CE-ESI-MS data obtained with BD-07 and BD-39
showed mass species with either one or two sialic acids (Table S1)
which are proposed to be derived from GM1 and GD1a mimicry
(Figure 4). Triple charged ion at m/z 1289.3 revealed a fragment
ion at m/z 290.2 (NeuAc) and none at 581.3 (NeuAc-NeuAc).
Since the composition of the triply charged ion at m/z 1289.3
contains two NeuAc, we conclude that these two residues are
present on different Gal residues, which is consistent with GD1a
mimicry. The glycosyltransferase variants in the LOS biosynthesis
locus of BD-07 and BD-39 are consistent with GM1/GD1a
mimicry (Table 3). They both contain a single domain glucosyl-
transferase (Cj1135) and an active b-1,3-galactosyltransferase
(Cj1136) which suggests that the inner core will be extended with
a Galb-b1,3-linked residue on HepII. The Gal residue will be
modified with a single NeuAc since the Cst-II variant in BD-07
and BD-39 is mono-functional (Thr51). The outer core is further
extended with GalNAc and Gal residues by variants of CgtA and
CgtB, respectively, which are specific for sialylated acceptors. The
terminal Gal residue is partially substituted by the mono-
functional Cst-II, which results in a mixture of GM1 and GD1a
mimicry.
CE-ESI-MS of O-deacylated LOS from strains BD-10 and BD-
67 resulted in spectra with similar mass species (Table S1). These
two strains also have LOS biosynthesis loci that are 100% identical
to each other (GenBank accession numbers GQ249164 and
GQ249165). We thus propose that they both express the same
LOS outer core, which appears to be a novel structure with two
extension sites from the inner core and two branches mimicking
GA2 and GD3, respectively (Figure 4). The presence of di-NeuAc
on one of the branches is confirmed by the fragment ion at m/z
581.3 when tandem mass spectrometry was carried out on the
triply charged ion at m/z 1302.3 (data not shown). The Cst-II
variant in these two strains is bi-functional (Asn51) which further
supports the presence of di-NeuAc. The absence of a terminal
Galb-1,3-linked residue is consistent with a cgtB gene that has
a frame-shift mutation.
Discussion
In Bangladesh, preceding infections with C. jejuni are identified
in the majority of patients with GBS [6]. In the current study we
provide evidence for the hypothesis that C. jejuni infections induce
GBS in these patients by molecular mimicry and induction of
a cross-reactive immune response to nerve ganglisoides. This
hypothesis is supported by our findings that [1] the serum IgG
response to C. jejuni LOS and to gangliosides are closely associated
in patients with GBS [2], patient serum anti-ganglioside IgG
antibodies cross-react to C. jejuni LOS [3], mouse monoclonal anti-
ganglioside antibodies cross-react to C. jejuni LOS [4], the C. jejuni
isolates from Bangladeshi GBS patients have a LOS biosynthesis
class A associated with ganglioside mimicry [5], and mass
spectrometry analysis of LOS from C. jejuni isolates from
Bangladeshi GBS patients demonstrated glycan structures that
are identical to those of gangliosides. To our knowledge, this is the
first report in which mass spectrometry is combined with DNA
sequence data to determine the LOS outer core structures of
neuropathy-associated C. jejuni strains isolated in South Asia. Our
data confirm that ganglioside mimicry is the most likely
pathogenic mechanism in the majority of C. jejuni-associated
GBS cases. Our data further support the hypothesis that
antecedent C. jejuni infections in GBS trigger the production of
antibodies that cross-react with gangliosides.
Molecular mimicry between gangliosides and LOS has been
demonstrated with C. jejuni isolates from GBS and MFS patients
[22,23,24,25,26,27]. Several findings in the current study support
Figure 2. Binding of mouse monoclonal antibodies against LOS from C. jejuni BD-07 and BD-39. DG-1 (binding to GM1), TBG-3 (binding
to GD1a), EG-7 (binding to GD1b), EG-3 (binding to GQ1b) and EG-1 (binding to GQ1b/GT1a).
doi:10.1371/journal.pone.0043976.g002
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the hypothesis that cross-reactive antibodies to ganglioside in these
patients contributed to the development of GBS in Bangladesh.
Anti-LOS antibody levels are significantly associated with GBS as
compared with data from two control groups (p,0.001). We
provide strong evidence that anti-LOS antibody levels are strongly
associated with recent C. jejuni infection in GBS patients. C. jejuni is
a frequent antecedent pathogen associated with GBS in Bangla-
desh [6]. The association between anti-LOS and anti-ganglioside
antibody reactivity is significant but not absolute. In some patients
with anti-ganglioside antibodies we did not find a high IgG activity
against LOS. This may result from relatively low titres or different
fine-specificities of the anti-ganglioside antibodies in these patients.
In our previous studies, we found no binding of anti-GM1
antibodies with LOS of C. jejuni from MFS and GBS patients [16].
There are some GBS patients without anti-ganglioside antibodies
but with anti-LOS antibodies. Patients with a C. jejuni infection
may have antibodies against complexes of gangliosides [17]. It is
interesting to note that our preliminary data showed that patients
Figure 3. ELISA analysis of the cross-reactivity of GBS patient’s serum anti-ganglioside antibodies to LOS from the autologous
C. jejuni strains. A) Optical density (OD) of IgG anti-GD1a reactivity in serum from patient DK-07 by pre-incubation with LOS from the autologous C.
jejuni BD-07 strain (GM1/GD1a mimic, Table 3) and from Penner HS:03 serostrain (CCUG 10937). B) Optical density (OD) of IgG anti-GM1 reactivity in
serum from patient DK-39 by pre-incubation with LOS from the autologous C. jejuni BD-39 strain (GM1/GD1a mimic, Table 3) and from Penner HS:03
serostrain (CCUG 10937). Graphs represent data as mean 6 standard error.
doi:10.1371/journal.pone.0043976.g003
Ganglioside Mimicry and Cross-Reactive Antibodies
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with anti-LOS reactivity but without reactivity against single
gangliosides can have antibodies against complexes gangliosides
(data not shown). Our results are in agreement with recent
observations that ganglioside complexes are important target
antigens in GBS as well as in MFS [28,29,30].
Monoclonal antibodies against gangliosides were bound by
LOS BD-07 and LOS BD-39 in a similar pattern. Serum DK-07
and DK-39 showed a dramatic reduction in anti- ganglioside
reactivity after incubation with the autologous LOSs. Incubation
with LOS that lacked ganglioside-mimics did not inhibit
ganglioside-reactivity, demonstrating that serum DK-07 and
serum DK-39 were specifically deprived of their ganglioside
antibodies by the incubation with the autologous LOSs. This
finding indicates that in these two GBS patients the antibodies
against GM1 and GD1a were induced by LOS during the
preceding C. jejuni infection. Immune response against C. jejuni is
involved in the pathogenesis of GBS by cross-reactivity with neural
tissue [17].
Various ganglioside mimics were found in the LOS of
neuropathy-associated strains in Bangladesh. Carbohydrate moi-
eties present in GM1 and GD1a were the most prevalent
ganglioside mimic in GBS-associated C. jejuni strains, and it was
predominantly found in LOS class A strains. This finding is
consistent with the results previously described [12,31], but in
contrast with those of Nachamkin et al. who reported previously
that the expression of GD1a, and not GM1 is associated with GBS
[32]. Mass spectrometry analysis has not demonstrated authentic
GQ1b-like structures in C. jejuni LOS. The detection of structures
with a terminal di-NeuAc-Gal in both strains (BD-10 and BD-67)
from Bangladesh associated with ophthalmoplegia suggests that in
these patients, pathogenic antibodies are raised against GA2- and
GD3-like LOS. Both strains express the same LOS outer core,
which appears to be a novel structure with two extension sites from
the inner core and two branches mimicking GA2 and GD3,
respectively. There are alternative explanations for the observation
that one GBS-associated strain (BD-94) did not express ganglioside
mimic in its LOS. It has been demonstrated previously that GBS
patients can occasionally be infected with two different C. jejuni
strains. In such cases only one of the strains could be linked to
GBS [12].
GBS is a clinically heterogeneous disorder, in which the
neurological deficits are partly related to the specificity of the
anti-ganglioside antibodies. In patients with preceding C. jejuni
infections, the specificity of these cross-reactive antibodies is
Figure 4. Proposed LOS outer core structures based on capillary-electrophoresis electrospray ionization mass spectrometry
analysis of O-deacylated LOS samples (see Table S1). (A) strains BD-07 and BD-39 show mimicry with GM1 and GD1a; (B) strains BD-10 and BD-
67 show mimicry with GA2 and GD3. Terminal regions mimicking gangliosides are indicated with arrows.
doi:10.1371/journal.pone.0043976.g004
Table 3. Variants of the glycosyltransferases involved in synthesis of LOS outer core structures in C. jejuni strains BD-07, BD-10, BD-
39 and BD-67a.
Strains LOS class
GeneBank
Accession No. Cj1135 Cj1136 CgtAI CgtAII CgtB Cst-II GalTg
BD-07 A GU289927 One-domain Onb Mono-sialyl.c Absent Mono-sialyl. Mono-f Absent
BD-10 B GQ249164 Two-domain On Non-sialyl.d Offe Off Bi- Present
BD-39 A GU289928 One-domain On Mono-sialyl. Absent Mono-sialyl. Mono- Absent
BD-67 B GQ249165 Two-domain On Non-sialyl. Off Off Bi- Present
aAssignment of the glycosyltransferase variants is based on amino acid sequence comparisons with variants of known specificities.
bon: indicates that a gene has no frame-shift mutation.
cMono-sialyl.: the glycosyltransferase is specific for mono-sialylated acceptors.
dNon-sialyl.: the glycosyltransferase is specific for non-sialylated acceptors.
eoff: indicates that a gene is inactive because of a frame-shift mutation.
fCst-II variants: mono-: monofunctional, Cst-II has a-2,3-sialyltransferase activity. bi-: bifunctional, Cst-II has both a-2,3-sialyltransferase and a-2,8-sialyltransferase activity.
gGalT: b-1,4-galactosyltransferase that uses Glcb-1,2-HepII- as acceptor.
doi:10.1371/journal.pone.0043976.t003
Ganglioside Mimicry and Cross-Reactive Antibodies
PLOS ONE | www.plosone.org 7 August 2012 | Volume 7 | Issue 8 | e43976
determined by the carbohydrate outer core of the C. jejuni LOS,
which is controlled by genetic polymorphisms. [26,33,34]. The
presence of, and polymorphism within the cstII gene in C. jejuni has
been associated with both the expression of ganglioside mimics
and the clinical features of patients with GBS [35,36]. The Thr51
variant was associated with monosialylated LOS and seemed to
occur more frequently in class A strains and in GBS-related strains
(BD-07 and BD-39). We found that the CstII Asn51 variant was
associated with the expression of disialylated LOS and seemed to
occur more frequently in class B strains, and strains related with
clinical symptoms of MFS or GBS with ophthalmoplegia.
Patients DK-07 and DK-39 have developed interesting immune
responses. Bacterial genotypying showed that these patients were
infected with clonal C. jejuni strains [37]. Mass spectrometry results
and our LOS characterization data demonstrated that LOS BD-
07 and BD-39 share the same ganglioside mimics. However,
patient DK-07 developed an anti-GD1a immune response while
patient DK-39 developed an anti-GM1 immune response. These
results suggest that the immune response against gangliosides is not
only determined by ganglioside mimicry present in the C. jejuni
LOS but may also be determined by host genetic factors.
In conclusion, our study further supports the hypothesis that
infections with specific C. jeuni strains induce cross-reactive IgG
antibodies against LOS and gangliosides in GBS patients. The
conformation of the oligosaccharide moieties in C. jejuni LOS and
the induction of anti-ganglioside antibodies by the adaptive
immune system cannot be predicted by the biochemical structure
only. Further research is necessary to elucidate the mechanism by
which C. jejuni determines the fine-specificity of the anti-
ganglioside antibodies.
Supporting Information
Figure S1 Serum antibodies to ganglioside cross-re-
acted with LOS from the autologous C. jejuni strains
(circles) but not with LOS from the control Penner HS:03
serostrain (CCUG 10937) lacking ganglioside mimicry
(diamonds). A) Inhibition of IgG anti-GD1a reactivity in serum
from patient DK-07 by pre-incubation with LOS from the
autologous C. jejuni BD-07 strain and from Penner HS:03
serostrain (CCUG 10937). B) Inhibition of IgG anti-GM1
reactivity in serum from patient DK-39 by pre-incubation with
LOS from the autologous C. jejuni BD-39 strain and from Penner
HS:03 serostrain (CCUG 10937).
(TIF)
Table S1 Negative ion ESI-MS data and proposed
compositions for O-deacylated LOS from Campylobac-
ter jejuni BD-07, BD-10, BD-39, BD-67 and BD-94.
(DOC)
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